The partnership will focus on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose monitoring (CGM) tools outside the Type 1 diabetes market, which includes inpatient hospital use, Type 2 diabetes and gestational diabetes, according to a news release.
San Diego-based Dexcom acquired its automated insulin delivery technology from Virginia-based startup TypeZero Technologies in 2018 and established a Charlottesville, Va., office, offering opportunities to collaborate with the University of Virginia, which is located in Charlottesville.
Dexcom’s next-generation closed-loop algorithms will be refined and piloted in a series of clinical trials as part of the collaboration, while the company’s Charlottesville team will expand in conjunction with the research collaboration, which will be spearheaded by the university’s Center for Diabetes Technology and will engage the School of Engineering, the School of Data Science and the School of Medicine at the university.
“Dexcom is committed to bringing innovative continuous glucose monitoring-based solutions to empower customers and clinicians toward greater health outcomes,” Dexcom chairman, president & CEO Kevin Sayer said in the release. “We are investing heavily in research and development efforts that explore new diagnostic tools and treatments. By partnering with a top-tier research institution like the University of Virginia, we hope to bring better CGM solutions to patients much faster than we could alone.”
Dexcom and the University of Virginia intend to commence their partnership in late 2020, with the company providing research funding to the university over a five-year period.
“The University of Virginia has become one of the world’s leading research institutes for diabetes technology,” University of Virginia president Jim Ryan said. “This expanded commitment from Dexcom ensures that research conducted on Grounds has a clear path to enrich and improve the lives of patients and caregivers managing this complicated and all too common disease.”